Show simple item record

dc.contributor.authorWhite, Danielle
dc.contributor.authorMoore, Gary W
dc.contributor.authorBesser, Martin
dc.contributor.authorMacDonald, Stephen
dc.contributor.authorThomas, Will
dc.date.accessioned2022-01-28T16:44:25Z
dc.date.available2022-01-28T16:44:25Z
dc.date.issued2022-01
dc.date.submitted2021-09-20
dc.identifier.issn2475-0379
dc.identifier.otherrth212648
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/333287
dc.description.abstractBACKGROUND: The optimal method of detecting a lupus anticoagulant (LA) for patients taking direct factor Xa inhibitor (DFXaI) direct oral anticoagulants (DOACs) remains controversial. Methods include charcoal adsorption of the DOACs to allow testing with the activated partial thromboplastin time (APTT) and dilute Russell viper venom time (dRVVT), or use of the DFXaI-insensitive Taipan snake venom time (TSVT) and Ecarin time (ET) assays on neat plasma. OBJECTIVES: The objective was to compare the utility of APTT and dRVVT analysis following DOAC Remove against TSVT/ET on untreated plasma for LA detection in spiked plasmas and routine clinical samples for patients on DFXaIs. PATIENTS/METHODS: Various LA-negative and LA-positive samples were assayed by APTT, dRVVT, and TSVT/ET, and then separately spiked with rivaroxaban, apixaban, and edoxaban calibrators to a concentration of ~190 ng/ml and the assays repeated on spiked plasma before and after DOAC Remove treatment. Testing of 284 consecutive samples from DFXaI-anticoagulated patients by APTT/dRVVT and TSVT/ET before and after DOAC Remove treatment was undertaken. RESULTS: In the spiking model, we found that both TSVT/ET and DOAC Remove strategies generally distinguished LA-negative and LA-positive samples, but some false-positive LA results occurred. In the investigation of 284 consecutive patient samples on DFXaIs, the percentage agreement for LA detection in neat samples tested by TSVT/ET versus APTT and dRVVT after DOAC Remove treatment was 90% (Cohen kappa 0.12). CONCLUSION: Our data highlight uncertainty and disagreement for testing LA in patients on DFXaI. Further studies are required.
dc.languageen
dc.publisherElsevier BV
dc.subjectDOAC Remove™
dc.subjectTaipan snake venom time
dc.subjectantiphospholipid syndrome
dc.subjectcharcoal adsorption
dc.subjectfactor Xa inhibitor
dc.subjectlupus anticoagulant
dc.titleDirect oral anticoagulants-Remove versus Taipan snake venom time for detection of a lupus anticoagulant in patients taking oral direct factor Xa inhibitors.
dc.typeArticle
dc.date.updated2022-01-28T16:44:24Z
prism.issueIdentifier1
prism.publicationNameRes Pract Thromb Haemost
prism.volume6
dc.identifier.doi10.17863/CAM.80710
dcterms.dateAccepted2021-11-24
rioxxterms.versionofrecord10.1002/rth2.12648
rioxxterms.versionAO
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.contributor.orcidWhite, Danielle [0000-0002-7711-6875]
dc.contributor.orcidThomas, Will [0000-0001-8740-0194]
dc.identifier.eissn2475-0379
cam.issuedOnline2022-01-23


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record